KEMPHARM INC (KMPH)

US4884452065 - Common Stock

5.81  -0.02 (-0.34%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KMPH. KMPH was compared to 198 industry peers in the Pharmaceuticals industry. KMPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KMPH is quite expensive at the moment. It does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

KMPH had negative earnings in the past year.
KMPH had a negative operating cash flow in the past year.
In the past 5 years KMPH always reported negative net income.
KMPH had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

KMPH has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KMPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

KMPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KMPH has more shares outstanding
The debt/assets ratio for KMPH has been reduced compared to a year ago.

2.2 Solvency

KMPH has an Altman-Z score of 1.51. This is a bad value and indicates that KMPH is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KMPH (1.51) is better than 65.16% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that KMPH is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.14, KMPH is in line with its industry, outperforming 42.99% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC8.07%

2.3 Liquidity

KMPH has a Current Ratio of 10.10. This indicates that KMPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.10, KMPH belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
KMPH has a Quick Ratio of 10.10. This indicates that KMPH is financially healthy and has no problem in meeting its short term obligations.
KMPH has a better Quick ratio (10.10) than 82.35% of its industry peers.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.83% over the past year.
KMPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.30%.
EPS 1Y (TTM)64.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-280%
Revenue 1Y (TTM)-62.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q46.26%

3.2 Future

The Earnings Per Share is expected to grow by 37.57% on average over the next years. This is a very strong growth
Based on estimates for the next years, KMPH will show a very strong growth in Revenue. The Revenue will grow by 29.23% on average per year.
EPS Next Y-143.91%
EPS Next 2Y-23.09%
EPS Next 3Y14.78%
EPS Next 5Y37.57%
Revenue Next Year-59.96%
Revenue Next 2Y-19.37%
Revenue Next 3Y11.18%
Revenue Next 5Y29.23%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KMPH. In the last year negative earnings were reported.
Also next year KMPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as KMPH's earnings are expected to grow with 14.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.09%
EPS Next 3Y14.78%

0

5. Dividend

5.1 Amount

KMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

KEMPHARM INC

NASDAQ:KMPH (2/28/2023, 7:00:03 PM)

5.81

-0.02 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap200.47M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)64.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-143.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-62.3%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y